Nasdaq · CIK 0001738021
CMPX Compass Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 10 d ago. Close $0.99 on Oct 9, 2026, +16% from the 52-week low and -85% from the high.
Last 90 days
Net insider value
+$21k
more bought than sold
Buys
2
$21k by 1 insider
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Price and insider trades, last year
CMPXOct 9, 2026 · close 0.99
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Compass Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 41Moderate | Neil Lerner Chief Accounting Officer buy | $18k 20,000 shares | +5% | 0% from low-87% from high | |
| 28Weak | Neil Lerner Chief Accounting Officer buy | $2,850 2,500 shares | +1% | 0% from low-83% from high | |
| 28Weak | Thomas J. Schuetz CHIEF EXECUTIVE OFFICER buy | $21k 10,000 shares | +0% | +56% from low-46% from high | |
| 68Notable | Orbimed Advisors LLC director, owner sell | $5.7M 3,571,428 shares | -100% | +30% from low-55% from high | |
| 68Notable | Carl L Gordon director, owner sell | $5.7M 3,571,428 shares | -100% | +30% from low-55% from high | |
| 46Moderate | Jonathan Anderman Gen Counsel & Corporate Sec buy | $31k 20,000 shares | +2000% | +16% from low-60% from high | |
| 39Weak | Neil Lerner CHIEF ACCOUNTING OFFICER buy | $28k 20,000 shares | +7% | +16% from low-60% from high |
Transactions
The last 21 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Neil Lerner Chief Accounting Officer | POpen-market purchase Common Stock | +20,000 | $0.92 | $18k | 420,000 | 10 d ago |
| Sep 24, 2026 | Neil Lerner Chief Accounting Officer | POpen-market purchase Common Stock | +2,500 | $1.14 | $2,850 | 400,000 | 17 d ago |
| May 27, 2025 | Thomas J. Schuetz CHIEF EXECUTIVE OFFICER | POpen-market purchase Common Stock | +10,000 | $2.11 | $21k | 6,480,825 | May 27, 2025 |
| Apr 9, 2025 | Orbimed Advisors LLC director, owner | SOpen-market sale Common Stockindirect: See footnotes | -3,571,428 | $1.59 | $5.7M | 0 | Apr 11, 2025 |
| Apr 9, 2025 | Carl L Gordon director, owner | SOpen-market sale Common Stockindirect: See footnotes | -3,571,428 | $1.59 | $5.7M | 0 | Apr 11, 2025 |
| Apr 7, 2025 | Jonathan Anderman Gen Counsel & Corporate Sec | POpen-market purchase Common Stock | +20,000 | $1.54 | $31k | 21,000 | Apr 8, 2025 |
| Apr 7, 2025 | Neil Lerner CHIEF ACCOUNTING OFFICER | POpen-market purchase Common Stock | +20,000 | $1.42 | $28k | 320,000 | Apr 8, 2025 |
| Feb 11, 2025 | Carl L Gordon director, owner | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Feb 13, 2025 |
| Feb 11, 2025 | Barry Shin CFO | AGrant or award Stock Option (Right to Buy)derivative | +250,000 | $0.00 | $0 | 250,000 | Feb 13, 2025 |
| Feb 11, 2025 | Thomas J. Schuetz CHIEF EXECUTIVE OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +1,500,000 | $0.00 | $0 | 1,500,000 | Feb 13, 2025 |
| Feb 11, 2025 | Richard S Lindahl director | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Feb 13, 2025 |
| Feb 11, 2025 | Neil Lerner SVP, CAO | AGrant or award Stock Option (Right to Buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Feb 13, 2025 |
| Feb 11, 2025 | Mary Ann Gray director | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Feb 13, 2025 |
| Feb 11, 2025 | Philip Ferneau director | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Feb 13, 2025 |
| Feb 11, 2025 | Ellen Chiniara director | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Feb 13, 2025 |
| Feb 11, 2025 | James P Boylan director | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Feb 13, 2025 |
| Feb 11, 2025 | Jonathan Anderman Sr VP, Gen Counsel & Corp Sec | AGrant or award Stock Option (Right to Buy)derivative | +280,000 | $0.00 | $0 | 280,000 | Feb 13, 2025 |
| Feb 8, 2025 | Thomas J. Schuetz CEO | FTax withholding Common Stock | -41,687 | $3.50 | $146k | 6,470,825 | Feb 11, 2025 |
| Jan 9, 2025 | Thomas J. Schuetz CEO | FTax withholding Common Stock | -58,054 | $1.86 | $108k | 6,512,512 | Jan 13, 2025 |
| Dec 9, 2024 | Barry Shin CFO | AGrant or award Common Stock | +400,000 | $1.65 | $660k | 400,000 | Dec 10, 2024 |
| Dec 9, 2024 | Barry Shin CFO | AGrant or award Stock Option (Right to Buy)derivative | +400,000 | $0.00 | $0 | 400,000 | Dec 10, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Jonathan AndermanGen Counsel & Corporate Sec
- James P Boylandirector
- Ellen Chiniaraofficer, director
- Philip Ferneaudirector
- Carl L Gordondirector, owner
- Mary Ann Graydirector
- Richard S Lindahlcfo, officer, director
- Neil LernerCHIEF ACCOUNTING OFFICER
- Orbimed Advisors LLCdirector, owner
- Thomas J. SchuetzCHIEF EXECUTIVE OFFICER
- Barry ShinCFO
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.